Equities research analysts predict that Thermo Fisher Scientific (NYSE:TMO) will post sales of $5.63 billion for the current fiscal quarter, Zacks reports. Seven analysts have issued estimates for Thermo Fisher Scientific’s earnings, with estimates ranging from $5.54 billion to $5.76 billion. Thermo Fisher Scientific posted sales of $4.77 billion in the same quarter last year, which would indicate a positive year-over-year growth rate of 18%. The firm is scheduled to announce its next quarterly earnings results before the market opens on Wednesday, April 25th.
On average, analysts expect that Thermo Fisher Scientific will report full year sales of $23.59 billion for the current year, with estimates ranging from $23.47 billion to $23.94 billion. For the next year, analysts anticipate that the business will post sales of $24.85 billion per share, with estimates ranging from $24.49 billion to $25.99 billion. Zacks Investment Research’s sales calculations are a mean average based on a survey of sell-side research firms that that provide coverage for Thermo Fisher Scientific.
Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings data on Wednesday, January 31st. The medical research company reported $2.79 earnings per share for the quarter, beating the consensus estimate of $2.66 by $0.13. Thermo Fisher Scientific had a return on equity of 16.01% and a net margin of 10.64%. The business had revenue of $6.05 billion for the quarter, compared to analysts’ expectations of $5.72 billion. During the same period last year, the business earned $2.41 EPS. The business’s revenue was up 22.1% on a year-over-year basis.
NYSE:TMO traded up $1.56 during trading hours on Friday, hitting $215.91. 808,780 shares of the company traded hands, compared to its average volume of 1,476,189. The company has a current ratio of 1.34, a quick ratio of 0.92 and a debt-to-equity ratio of 0.74. Thermo Fisher Scientific has a one year low of $152.30 and a one year high of $226.44. The stock has a market cap of $86,122.42, a PE ratio of 22.75, a price-to-earnings-growth ratio of 1.58 and a beta of 1.14.
The company also recently disclosed a quarterly dividend, which will be paid on Monday, April 16th. Investors of record on Thursday, March 15th will be issued a $0.17 dividend. The ex-dividend date is Wednesday, March 14th. This represents a $0.68 annualized dividend and a yield of 0.31%. This is a positive change from Thermo Fisher Scientific’s previous quarterly dividend of $0.15. Thermo Fisher Scientific’s dividend payout ratio (DPR) is 7.17%.
In related news, Director William G. Parrett sold 1,000 shares of Thermo Fisher Scientific stock in a transaction dated Thursday, February 15th. The stock was sold at an average price of $209.80, for a total value of $209,800.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Marc N. Casper sold 40,000 shares of Thermo Fisher Scientific stock in a transaction dated Thursday, March 22nd. The stock was sold at an average price of $210.16, for a total value of $8,406,400.00. Following the completion of the sale, the chief executive officer now directly owns 334,622 shares of the company’s stock, valued at approximately $70,324,159.52. The disclosure for this sale can be found here. In the last three months, insiders sold 88,827 shares of company stock valued at $19,012,672. 0.49% of the stock is currently owned by insiders.
A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Icon Wealth Partners LLC purchased a new position in Thermo Fisher Scientific during the 4th quarter valued at about $105,000. Bank of Nova Scotia Trust Co. purchased a new position in Thermo Fisher Scientific during the 3rd quarter valued at about $106,000. Keeler Thomas Management LLC purchased a new position in Thermo Fisher Scientific during the 4th quarter valued at about $106,000. Virtue Capital Management LLC purchased a new position in Thermo Fisher Scientific during the 4th quarter valued at about $127,000. Finally, Premia Global Advisors LLC purchased a new position in Thermo Fisher Scientific during the 4th quarter valued at about $131,000. 87.62% of the stock is owned by institutional investors.
ILLEGAL ACTIVITY NOTICE: “Brokerages Anticipate Thermo Fisher Scientific (TMO) Will Post Quarterly Sales of $5.63 Billion” was published by StockNewsTimes and is owned by of StockNewsTimes. If you are viewing this news story on another site, it was illegally copied and republished in violation of United States & international trademark & copyright laws. The original version of this news story can be viewed at https://stocknewstimes.com/2018/04/16/brokerages-anticipate-thermo-fisher-scientific-tmo-will-post-quarterly-sales-of-5-63-billion.html.
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc provides analytical instruments, equipment, reagents and consumables, software, and services for research, manufacturing, analysis, discovery, and diagnostics under the Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, and Unity Lab Services brands worldwide.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.